UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s shares closed last Friday at DKK637.20.

In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK600.00. The company’s shares closed ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Therefore, NVO looks like a no-brainer 'Strong buy' opportunity for me. Novo Nordisk is a global healthcare company headquartered in Denmark. The product's portfolio is mainly focused on diabetes ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28 ...

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... According to him, the "QTUM ETF that has almost no quantum computing, it's been bid up. I mean they really are ...

You wanna put, you wanna put the jugular? That’s Denmark’s jugular. “Well no Denmark it could lose Novo Nordisk, it could be great for Eli Lilly.” Overall NVO ranks 8th on our list of the ...

At Nordisk Insulinlaboratorium ... policymakers insist Novo should lower its costs. “If this persists, the economics around insulin could be no longer viable. That scares the hell out of me.” ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.